The Diagnostic Imaging MRI modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of MRI across the healthcare continuum, including breast, neurological, cardiovascular, prostate imaging, and more.
October 31st 2024
For patients with rectal cancer, an emerging nomogram that combines deep learning and clinical factors had greater than 16 percent and 23 percent increases in accuracy and specificity, respectively, for pre-op prediction of tumor deposits in comparison to clinical factors alone.
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?
View More
Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
View More
Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
Myocardial perfusion CT closes in on cardiac fMRI
June 3rd 2008With piles of accumulated evidence demonstrating the ability of multislice CT to diagnose coronary artery disease, researchers are expanding clinical application of the modality to the measurement of myocardial viability following infarction.
Kennedy brain tumor puts spotlight on new treatment
June 2nd 2008News of Sen. Edward Kennedy’s diagnosis with a malignant glioma shocked the nation. It has also raised awareness about the grim prognosis associated with this type of brain tumor. A new study conducted by the American College of Radiology’s Radiation Therapy Oncology Group could bring hope to glioma patients.
Trained specialists can explore US potential
May 19th 2008Liver imaging is benefiting considerably from the improvement of ultrasound systems and sequences dedicated to contrast-enhanced examinations. The use of ultrasound contrast to detect and characterize focal liver lesions is now routine.
Ovarian lesions pose diagnostic dilemmas
May 19th 2008The main objective of imaging patients with symptoms suggestive of ovarian lesions is to distinguish benign findings from malignant disease. Masses can be characterized with a variety of noninvasive imaging techniques, including transabdominal and transvaginal ultrasound, CT, and MRI. Each of these modalities has its advantages and limitations.
Whole-body cancer staging in some requires frequent follow-up
May 19th 2008Whole-body MRI is more sensitive but less specific than FDG-PET/CT for cancer detection, according to researchers from China and Europe. Findings suggest a complementary rather than exclusive role in oncologic imaging for both modalities and validate recent studies suggesting close follow-up since either test can miss metastases.
Role of gadolinium-based agents in NSF incidence remains unclear
May 19th 2008The controversial topic of nephrogenic systemic fibrosis featured prominently in this year’s European Congress of Radiology program. This scleroderma-like disorder has been linked to the administration of gadolinium-containing contrast media. Despite the growing wealth of data on incidence of the disorder, however, researchers remain unable to pin down the causal trigger.
MR imaging throws light on causes of epilepsy
An epileptic seizure is the external manifestation of a functional cerebral disorder that can affect 10% of the world's population. Virtually any brain abnormality can irritate vulnerable neurons and produce epileptic seizures. The nature and characteristics of the seizure depend on the part of the brain involved in the disturbance.
Perfusion MRI predicts malignant transformation of benign brain tumors
May 16th 2008Perfusion-weighted MR imaging can anticipate the transformation of low-grade gliomas into malignant tumors up to a year earlier than other imaging tests, according to British researchers. MRI could help determine which patients may benefit more from aggressive treatment.
MRI predicts prostate cancer prognosis
May 14th 2008Researchers in San Francisco have found that MR imaging can accurately predict recurrence and development of metastatic disease in patients who are about to undergo radiation therapy for prostate cancer. Study findings suggest a stronger role for MRI in the management of the condition.
Hitachi primes 1.2T Oasis for commercial launch
May 9th 2008Hitachi executives hope their booth at the ISMRM meeting will serve as a springboard for sales of their open 1.2T Oasis, set to begin shipping this month. The new high-field scanner is the company’s chance to rekindle a market that has all but collapsed in the past several years with the advent of compact wide-bore 1.5T devices and expanding clinical applications for such high-performance systems.
Siemens casts Tim as its unifying thread
May 9th 2008Above and around the Siemens Healthcare booth at the ISMRM meeting, the message “pushing the boundaries of MR” was as clear as it could be. The theme was driven home by pennants featuring iconic reconstructions of athletes into whole-body 2D renditions of muscles and organs. How the company pushes these boundaries, however, had been more subtext than headline, an issue Siemens vice president of marketing for MR Don Fowler set out to resolve on the ISMRM exhibit floor.
Functional brain mapping boosts early assessment of brain cancer treatment response
May 9th 2008The first three months after standard radiation therapy for a brain tumor must be hell for patients and their families. The established MacDonald criteria for assessing treatment force them to wait up to 10 weeks for follow-up CT or MR to determine if the size of the treated tumor has changed.
Cardiac coil boosts data acquisition on Toshiba 1.5T
May 7th 2008Quality Electrodynamics has constructed and tested a 32-channel cardiac array for use on the Toshiba 1.5T Vantage Atlas that its developers say will provide acceleration factors in any direction, including oblique phase-encoding, which is often applied in cardiac imaging.
Kaiser study of 3.3 million members finds single case of NSF
May 7th 2008A comprehensive evaluation of Magnevist use among the 3.3 million members of Kaiser Permanente in Northern California has found a lower risk for developing nephrogenic systemic fibrosis than reported in previous studies in renal disease patients who received gadolinium-based MR contrast media.
Philips advances quantitative MR
May 7th 2008Quantitative MR, characterized by the precise measurement of data points that underlie MR images, may one day provide an exact and definable basis to recognize the early signs of disease and response to therapy. Philips Healthcare is moving toward that day, developing techniques that quantify the presence of cancerous tumors and heart disease.
Desk-sized MR scanner shows potential for rheumatoid arthritis patients
May 7th 2008Assessment with MR is essential for the early detection of rheumatoid arthritis in the hands and the monitoring of drug therapy, but hand studies are not cost effective. That’s where the Japanese firm MR Technology of Tsukuba, in the prefecture of Ibaraki, comes in.
Merck plans evaluation of spin-signal MR
May 6th 2008GE Healthcare’s gas-based MRI imaging strategy may find a home, if tests of the technology by Merck pan out. The pharmaceutical company plans to audition GE’s Spin Signal Technology (SST) utilizing hyperpolarized xenon 129 gas for use in assessing its experimental respiratory treatments.